NanoVax Therapeutics

NanoVax Therapeutics, Inc. is a biotechnology startup developing next-generation cancer vaccines inspired by the immune-stimulating properties of pathogens. Our proprietary lipid nanoparticle platform delivers powerful combinations of innate immune agonists and tumor antigens to prime and direct robust, tumor-specific T cell responses.

Founded out of the Atukorale Lab at UMass Amherst and UMass Chan Medical School, NanoVax is advancing toward first-in-human studies with support from translational funding. We are committed to developing curative, immune-based treatments for patients with limited options.